Aroxxen® Inhalation for Cardioprotection After Elective PCI With Stent Implantation

A phase 2 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 180 participants.

Also called NCT07397351

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose supportive care
Phase
Phase 2
Enrolled
  • 180 participants (planned count) (from the registry)
Sponsor
Research Institute of Geroprotective Technologies (from the registry)
Registry
  • NCT NCT07397351
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Russia (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT07397351. Randomized; no masking; primary purpose supportive care. Start 2026-03-05 (actual); primary completion 2026-10-01 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Aroxxen® Inhalation for Cardioprotection After Elective PCI With Stent Implantation
Intervention (Drug)
Aroxxen
Lead sponsor
Research Institute of Geroprotective Technologies (class: industry)

Record details

Record id
cardio:ct-nct07397351
Content hash
10f8cbba998fade52fb034a7d3620d8c6b88fc9cff3662982e3fc26f493a4cfd